UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Genotypic and phenotypic comparisons of de Novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model

Cancer research (Chicago, Ill.), 2003-11, Vol.63 (22), p.7900-7906

2003

Volltextzugriff (PDF)

The tumor microenvironment shapes hallmarks of mature B-cell malignancies

Oncogene, 2015-09, Vol.34 (36), p.4673-4682

2015

Volltextzugriff (PDF)

Cancer Biomarkers--An Invitation to the Table

Science (American Association for the Advancement of Science), 2006-05, Vol.312 (5777), p.1165-1168

2006

Volltextzugriff (PDF)

Myc represses miR-15a miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas

Oncogene, 2012-06, Vol.31 (24), p.3002-3008

2012

Volltextzugriff (PDF)

Drug resistance in multiple myeloma: approaches to circumvention

Seminars in oncology, 1999-10, Vol.26 (5 Suppl 13), p.23-27

1999

Volltextzugriff (PDF)

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

The New England journal of medicine, 2005-06, Vol.352 (24), p.2487-2498

2005

Volltextzugriff (PDF)

Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms

Leukemia, 2003-06, Vol.17 (6), p.1175-1182

2003

Volltextzugriff (PDF)

Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas

Leukemia, 2011-01, Vol.25 (1), p.145-152

2011

Volltextzugriff (PDF)

Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines

Blood, 2004-05, Vol.103 (9), p.3503-3510

2004

Volltextzugriff (PDF)

P-Glycoprotein Expression and Function in Circulating Blood Cells From Normal Volunteers

Blood, 1994-05, Vol.83 (9), p.2451-2458

1994

Volltextzugriff (PDF)

Cell adhesion mediated drug resistance (CAM-DR) : Role of integrins and resistance to apoptosis in human myeloma cell lines

Blood, 1999-03, Vol.93 (5), p.1658-1667

1999

Volltextzugriff (PDF)

Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death

Oncogene, 2003-10, Vol.22 (47), p.7396-7402

2003

Volltextzugriff (PDF)

Overexpression of the Major Vault Transporter Protein Lung-Resistance Protein Predicts Treatment Outcome in Acute Myeloid Leukemia

Blood, 1996-03, Vol.87 (6), p.2464-2469

1996

Volltextzugriff (PDF)

Synopsis of a Research Roundtable Presented on Cell Signaling in Myeloma: Regulation of Growth and Apoptosis—Opportunities for New Drug Discovery

Molecular cancer therapeutics, 2002-12, Vol.1 (14), p.1361-1365

2002

Volltextzugriff (PDF)

Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells

Immunity (Cambridge, Mass.), 1999, Vol.10 (1), p.105-115

1999

Volltextzugriff (PDF)

Phase III study of PSC-833 (Valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) : A trial of the eastern cooperative oncology group

Cancer, 2006-02, Vol.106 (4), p.830-838

2006

Volltextzugriff (PDF)

Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells

Oncogene, 2003-04, Vol.22 (16), p.2417-2421

2003

Volltextzugriff (PDF)

The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells

Blood, 2005-07, Vol.106 (2), p.698-705

2005

Volltextzugriff (PDF)

Ascorbic acid enhances arsenic trioxide–induced cytotoxicity in multiple myeloma cells

Blood, 2001-08, Vol.98 (3), p.805-813

2001

Volltextzugriff (PDF)

Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia

Clinical cancer research, 2006-01, Vol.12 (2), p.591-599

2006

Volltextzugriff (PDF)

The tumor microenvironment: focus on myeloma

Cancer treatment reviews, 2003-05, Vol.29, p.11-19

Dalton, William S

2003

Volltextzugriff (PDF)

Cell Adhesion Is a Key Determinant in de Novo Multidrug Resistance (MDR): New Targets for the Prevention of Acquired MDR

Molecular cancer therapeutics, 2001-11, Vol.1 (1), p.69-78

2001

Volltextzugriff (PDF)

The proteasome

Seminars in oncology, 2004-12, Vol.31 (6 Suppl 16), p.3-9

Dalton, William S.

2004

Volltextzugriff (PDF)

Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray

Cancer research (Chicago, Ill.), 2000-08, Vol.60 (15), p.4161-4166

2000

Volltextzugriff (PDF)

1 – 25 von 170

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(141)

Publikationsform

Artikel
(170)

Sprache

Englisch
(170)

Erscheinungsjahr

n.n

Thema

Science & Technology
(155)
Life Sciences & Biomedicine
(147)
Humans
(128)
Oncology
(86)
Biological And Medical Sciences
(81)
Medical Sciences
(77)
Pharmacology. Drug Treatments
(54)
Antineoplastic Agents
(50)
Drug Resistance
(38)
Tumor Cells, Cultured
(38)
Hematology
(35)
General Aspects
(34)
Female
(32)
Animals
(30)
Drug Resistance, Neoplasm
(30)
Male
(25)
Multiple Myeloma - Drug Therapy
(25)
Antineoplastic Agents - Pharmacology
(24)
Multiple Myeloma - Metabolism
(24)
Apoptosis
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(23)
Cancer Research
(17)
Clinical Cancer Research
(8)
Jnci : Journal Of The National Cancer Institute
(6)
Leukemia
(6)
Biochemical Pharmacology
(5)
Oncogene
(5)
Seminars In Oncology
(5)
Current Opinion In Oncology
(4)
Leukemia & Lymphoma
(4)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Genotypic and phenotypic comparisons of de Novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model

The tumor microenvironment shapes hallmarks of mature B-cell malignancies

Cancer Biomarkers--An Invitation to the Table

Myc represses miR-15a miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas

Drug resistance in multiple myeloma: approaches to circumvention

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms

Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas

Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines

P-Glycoprotein Expression and Function in Circulating Blood Cells From Normal Volunteers

Cell adhesion mediated drug resistance (CAM-DR) : Role of integrins and resistance to apoptosis in human myeloma cell lines

Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death

Overexpression of the Major Vault Transporter Protein Lung-Resistance Protein Predicts Treatment Outcome in Acute Myeloid Leukemia

Synopsis of a Research Roundtable Presented on Cell Signaling in Myeloma: Regulation of Growth and Apoptosis—Opportunities for New Drug Discovery

Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells

Phase III study of PSC-833 (Valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) : A trial of the eastern cooperative oncology group

Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells

The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells

Ascorbic acid enhances arsenic trioxide–induced cytotoxicity in multiple myeloma cells

Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia

The tumor microenvironment: focus on myeloma

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

Cell Adhesion Is a Key Determinant in de Novo Multidrug Resistance (MDR): New Targets for the Prevention of Acquired MDR

The proteasome

Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray

Suchergebnisse filtern